Morgan Stanley analyst Terence Flynn maintains $CRISPR Therapeutics (CRSP.US)$ with a sell rating, and maintains the target price at $45.
According to TipRanks data, the analyst has a success rate of 54.2% and a total average return of 8.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $CRISPR Therapeutics (CRSP.US)$'s main analysts recently are as follows:
The company's Q3 update underscored the CTX112 ASH abstract focusing on B-cell malignancies, which demonstrated promising initial efficacy.
Crispr Therapeutics' progression post Q3 has been monitored, with indications of demand increment. The treatment process is not rapid; however, there is evidence of patient engagement, with the first patient having received treatment and a total of forty patients having completed at least one cell collection phase. Caution is exercised in assessing the timeline necessary for patients to contribute to revenue and profitability. Upcoming insights are anticipated from the CTX112 ASH2024 abstract, which reported a six-month complete response rate of 44% in a basket lymphoma study, and will be crucial in evaluating the company's prospects in oncology and autoimmune diseases.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Terence Flynn維持$CRISPR Therapeutics (CRSP.US)$賣出評級，維持目標價45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為54.2%，總平均回報率為8.3%。
此外，綜合報道，$CRISPR Therapeutics (CRSP.US)$近期主要分析師觀點如下：
該公司的第三季度更新強調了以b細胞惡性腫瘤爲重點的 CTX112 ASH 摘要，該摘要顯示出令人鼓舞的初步療效。
Crispr Therapeutics在第三季度之後的進展已受到監測，有跡象表明需求有所增加。治療過程並不迅速；但是，有證據表明患者參與其中，第一位患者接受了治療，共有40名患者完成了至少一個細胞收集階段。在評估患者爲收入和盈利能力做出貢獻所需的時間表時要謹慎行事。預計即將發佈的見解將來自 CTX112 ASH2024 摘要，該摘要報告稱，在一項籃子淋巴瘤研究中，六個月的完整答覆率爲44％，這將對評估該公司在腫瘤學和自身免疫性疾病方面的前景至關重要。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
